Skip to content

MEDIGENA

Active Private limited companyfounded 2023active for 3 yearsChaussée de Namur, Natoye 73, 5360 HamoisKBO/BCE: BE 0803.437.439 subsidiary of

Annual accounts 2025

micro format, filed on 09-08-2026, 9 days late
€88,886
▼ 26.0%
€31,633
▼ 55.3%
€14,379
▼ 73.4%
-€17,103
▼ €7,799
6.1%
▼ 0.2 percentage points
0.79
▼ 0.12

Turnover is estimated at about €200,000, probably between €150,000 and €250,000. The micro format does not state turnover.

Balance sheet

balance sheet total €488,155 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

6.1%

Higher than 11% of the 21,373 companies filing micro accounts in human health (NACE 86) in 2025.

0.79

Higher than 12% of the 20,922 companies filing micro accounts in human health (NACE 86) in 2025.

2.9%

Higher than 12% of the 21,223 companies filing micro accounts in human health (NACE 86) in 2025.

MEDIGENA Middle half of the sector 80% of the sector Micro accounts in human health (NACE 86)

Net result: bottom quarter · Equity: bottom quarter · Balance sheet total: middle half · Working capital: bottom quarter

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend2025202420236 months
88,356119,36840,572
71,102102,64735,381
12,856131,623405,000
-5,255-31,576-
-17,103-9,30414,530
6.1%6.3%7.0%
0.790.921.27
15.2714.8413.21
47.9%150.4%45.1%
2.9%9.5%3.2%
5.127.148.99

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend2025202420236 months
Balance sheet: assets
20/58 488,155569,190452,828
21/28 423,169467,035383,995
21 299,836339,836379,836
22/27 123,333127,2004,160
24 108,301110,4104,160
26 15,03216,789-
29/58 64,986102,15568,833
40/41 36,41068,3243,426
40 -091
41 36,41068,3243,335
54/58 28,57633,83165,407
Balance sheet: equity and liabilities
10/49 488,155569,190452,828
10/15 30,00035,94031,876
10/11 30,00030,00030,000
14 05,9401,876
17/49 458,155533,250420,953
17 369,236415,006362,529
170/4 369,236415,006362,529
42/48 82,090111,46054,303
42 45,77044,04834,141
44 15,74217,4121,230
440/4 15,74217,4121,230
45 -0680
450/3 -0680
47/48 20,57850,00018,253
492/3 6,8296,7844,120
Income statement
9900 88,886120,04541,007
630 56,72348,58321,005
640/8 530677434
9901 31,63370,78519,568
65/66B 17,25416,7214,512
65 17,25416,7214,512
9903 14,37954,06515,056
67/77 -0680
9904 14,37954,06514,376
9905 14,37954,06514,376
Appropriation of the result
9906 20,32055,94014,376
14P 5,9401,876-
694/7 20,32050,00012,500
694 11,840--
695 8,48050,00012,500
Document PDFPDFPDF

The full notes are in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 09-08-2026.

Filings

each dot is a set of accounts, on the day it reached the National Bank

The accounts were filed on 09-08-2026. The deadline was 31-07-2026, 7 months after the close on 31-12-2025 (article 3:10 of the Companies and Associations Code). Source: NBB, 2026-00391430.

Financial year Type Filed Reference Document
31-12-2025 micro format 09-08-2026 2026-00391430 PDF
31-12-2024 micro format 22-08-2025 2025-00401677 PDF
31-12-2023 micro format 24-08-2024 2024-00366288 PDF

Investments

fixed assets acquired
Item202520242023
Tangible fixed assets€12,856€131,623€5,000
Intangible fixed assets--€400,000
€56,723€48,583€21,005

Source: notes to the 2023 to 2025 annual accounts (statement of fixed assets)

Insights on MEDIGENA

The operating result for 2025 is 55% lower than in 2024.

Debt's share of the balance-sheet total rises from 93.7% to 93.9%. Equity and debt are lower.

Next steps